All In Biotech

Drug Trial Radar · NCT01833741

A Study of LUMIGAN® RC in the Clinical Setting

Last checked: Nov 19, 2026Latest source record: Sep 26, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,137

Actual

Start

Dec 2009

Primary completion

Mar 2011

Study completion Mar 2011

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Apr 17, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.

Conditions

  • Glaucoma, Primary Open Angle
  • Ocular Hypertension

Interventions

  • Bimatoprost 0.01%Drug

    Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Treatment-Naive Patients With Ocular HyperemiaTime frame: Week 12
  2. Percentage of Previously Treated (Switched) Patients With Ocular HyperemiaTime frame: Week 12
  3. Percentage of Patients Treated With Adjunctive Therapy With Ocular HyperemiaTime frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Barrie, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.